Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Bitterroot Bio logo — Bitterroot Bio leverages the power of immunotherapy to devel...

Bitterroot Bio

Bitterroot Bio leverages the power of immunotherapy to develop and deliver novel medicines for cardiovascular disease.

Founded 2021 11-50 employees Series A Total: $145.00M Biotechnology

General Information

Company Name Bitterroot Bio
Founded Year 2021
Employees 11-50
Industries Biotechnology
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Bitterroot Bio. To contact Bitterroot Bio, visit brbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Bitterroot Bio

Bitterroot Bio is a biotechnology startup founded in 2021, dedicated to leveraging the power of immunotherapy to develop and deliver novel medicines for cardiovascular disease. The company recently secured a substantial $145.00M Series A investment on 07 June 2023 from a group of prominent investors including Arch Venture Partners, GV, Alexandria Venture Investments, Deerfield Management, and Koch Disruptive Ventures. This funding is expected to fuel Bitterroot Bio's research and development efforts and propel its mission to advance innovative treatments in the field of cardiovascular health. As a significant player in the biotechnology industry, Bitterroot Bio's progress and advancements are worth keeping an eye on for potential investment opportunities.

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $145.00M 5
Arch Venture Partners GV Alexandria Venture Investments
Arch Venture Partners, GV +3
07 Jun 2023

Bitterroot Bio Alternatives & Competitors

View All Alternatives
Bitterroot Bio vs
Circio Holding ASA
Circio Holding ASA Norway

Developing novel circular RNA and immunotherapy medicines.

Post-IPO Debt
20 employees
Biotechnology, Health Care
Bitterroot Bio vs
CardiaTec Bio
CardiaTec Bio United Kingdom

Decoding cardiovascular disease biology for novel therapeutic discovery

Pre-Seed
16 employees
AI, Biotechnology
Bitterroot Bio vs
Shockwave Medical
Shockwave Medical United States

Making waves for underserved patients with cardiovascular disease via novel technologies. ⚡🌊

Post-IPO Debt
1369 employees
Biotechnology, Health Care
View all alternatives

FAQ About Bitterroot Bio

Bitterroot Bio leverages the power of immunotherapy to develop and deliver novel medicines for cardiovascular disease.
Bitterroot Bio was founded in 2021.
Bitterroot Bio operates in Biotechnology.
Bitterroot Bio has approximately 11-50 employees.
Bitterroot Bio has completed 1 funding round, raising a total of $145.00M. The latest funding stage is Series A.
Top alternatives and competitors to Bitterroot Bio include Circio Holding ASA , CardiaTec Bio, Shockwave Medical, Qlaris Bio, Inc., Aptabridge Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Bitterroot Bio and Circio Holding ASA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Bitterroot Bio, https://bouncewatch.com/company/bitterroot-bio, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes